TB-500 Benefits, Results, and What to Expect

TB-500 is a synthetic fragment of thymosin beta-4, a protein found naturally in many tissues. It sits in the tissue-repair corner of the research literature, usually mentioned alongside BPC-157, and the questions people ask most are what it is studied for, how long results are framed to take, and why protocols split into loading and maintenance phases. This is a neutral, third-person overview of all three.

TB-500 is a research compound, not approved for human consumption, and nothing here is medical or dosing advice. The descriptions below are reference profiles from laboratory and animal studies, not promises of an outcome. Any decision about use belongs with a licensed clinician. To run the reconstitution and unit math instead of guessing, use the TB-500 calculator.

What TB-500 is studied for

Thymosin beta-4 is best known in research for binding actin, a protein central to how cells build their internal scaffolding and move. That single mechanism is why most discussed benefits trace back to cell migration and tissue remodeling rather than to one organ or one injury.

• Cell migration: research models describe thymosin beta-4 helping repair-related cells move toward an area of interest.
• Tissue remodeling: studied in connection with the structural rebuilding that follows tissue stress.
• Flexibility and range: anecdotal and research discussion often frames it around connective tissue and joint mobility.
• Recovery framing: commonly grouped with BPC-157 in repair-pathway research rather than studied in isolation.

Tissue repair and flexibility, in plain terms

The reason TB-500 gets grouped with flexibility and range-of-motion discussion is the actin mechanism. Connective tissue, tendon, and muscle all rely on cells moving and reorganizing during remodeling, and that is the process thymosin beta-4 is studied around. The systemic profile matters here too: unlike a localized compound, TB-500 is more often described as distributing broadly after injection, so the research framing is whole-body rather than one spot.

This is also where TB-500 and BPC-157 get compared. The common framing is complementary rather than redundant: one is described as localized, the other as systemic. If you want that side by side, see BPC-157 vs TB-500 and the BPC-157 and TB-500 stack protocol for how the pair is structured in research.

What a realistic timeline looks like

Most reference discussion frames TB-500 as a multi-week compound, not a same-day one. Protocols are typically described in two stages: a loading span of several weeks where draws are more frequent, followed by a maintenance span at a lower frequency. The timeline below is how the literature structures the schedule, not a prediction of results or a recommendation.

• Weeks 1 to 4 to 6: the loading window, where references describe more frequent draws and a higher weekly total.
• After loading: a maintenance window, where the same per-draw figure is taken less often.
• Cycling: many protocols are framed as on-and-off rather than continuous; see how long to cycle peptides for the general structure.

Loading vs maintenance: the structure

The split between loading and maintenance is about frequency, not about changing the per-draw amount. In most reference protocols the milligram figure per draw stays in a similar range across both phases; what changes is how many draws happen per week. That is the single most useful thing to understand about how TB-500 schedules are written.

A worked arithmetic example makes it concrete. Take a 10 mg vial in 2 mL of bacteriostatic water, which gives 5 mg/mL, and a 2 mg reference draw. At 5 mg/mL, 2 mg is 0.4 mL, or 40 units on a U-100 insulin syringe.

• Loading week: two 2 mg draws = 4 mg total = 80 units of liquid across the week.
• Maintenance week: one 2 mg draw = 2 mg total = 40 units across the week.
• Per draw, unchanged: 2 mg = 40 units in both phases; only the number of draws moves.

These figures are illustrations of how frequency drives the weekly total, not recommendations. The deeper schedule breakdown lives in the TB-500 dosage guide, and you can map any milligram figure to units with the mg to units calculator.

Getting the math right

Benefits discussion is the soft part of any peptide topic; the math is the part you can get exactly right. Concentration drives everything: concentration = vial strength divided by water volume, draw volume = dose divided by concentration, and units = draw volume times 100 on a U-100 syringe. Set the concentration once, log every vial and water volume, and recompute from scratch whenever any of those three numbers changes.

For the full mixing sequence see how to reconstitute peptides, and use the TB-500 calculator to turn a vial and a target figure into a unit count without doing the arithmetic by hand. See the disclaimer for the limits of this reference information.